C-peptide is described as a key biomarker for beta cell function in type 1 diabetes and a potential surrogate endpoint for drug approval. Current trial endpoints remain difficult for disease-modifying therapies.
January and March 2026 drug pipeline updates included Phase 3 results, Fast Track designations and Priority Review decisions across multiple disease areas. Mavacamten, teplizumab-mzwv, anifrolumab, AXS-05, gedatolisib and AFTX-201 were among the programs with notable milestones.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07395050 |
Autologous CD6-CAR Treg Cells for Patients With Stage 3 Type 1 Diabetes |
NOT_YET_RECRUITING | EARLY_PHASE1 |
